Pelvic perfusion for localy advanced tumors;La perfusion pelvienne sous circulation extracorporelle dans les tumeurs pelviennes localement évoluées

Bulletin du Cancer

Volumn 96, Issue 1, 2009, Pages 103-109

  Bonvalot, Sylvie ^a   Muret, Jane ^a   Debaere, Thierry ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Pelvic perfusion; Regional chemotherapy; Surgery; TNF

Indexed keywords

CISPLATIN; FLUOROURACIL; MELPHALAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AORTA FLOW; BALLOON OCCLUSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CAVA VEIN; COLORECTAL CANCER; GYNECOLOGIC CANCER; HUMAN; LOW DRUG DOSE; MAST SUIT; PELVIC PERFUSION; PERFUSION; REVIEW; VEIN BLOOD FLOW; ANIMAL; CATTLE; COLORECTAL TUMOR; FEMALE; FEMALE GENITAL TRACT TUMOR; MALE; METHODOLOGY; PATHOLOGY; PELVIS TUMOR; PHASE 3 CLINICAL TRIAL; REGIONAL PERFUSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MALE; MELPHALAN; PELVIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61549106855     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0803     Document Type: Review

References (30)

1. Crowe PJ, Temple WJ, Lopez MJ, Ketcham AS. Pelvic exenteration for advanced pelvic malignancy. Semin Surg Oncol 1999 ; 17 : 152-60.
2. Creech O, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer : regional perfusion utilizing an extra corporeal circuit. Ann Surg 1958 ; 148 : 616-32.
3. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res 1979 ; 39 : 2264-8.
4. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad 5ci 1975 ; 72 : 3666-70.
5. de Wilt JH, ten Hagen Tl-, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000 ; 82(5) : 1000-3.
6. De Wilt JH, Manusama ER, van Tiel ST, van Ijken MG, ten Hagen TL, Eggermont AM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999 ; 80(1-2) : 161-6.
7. Eggermont A, Schraffordt Koops H, Liénard J, Ouderk M. Destruction of tumor associated vessels by isolated limb perfusion with TNF : angiographic observations in sarcoma patients. Eur J Surg Oncol 1994 ; 20 : 403-4.
8. Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 1988 ; 62(12) : 2467-71 (15).
9. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992 ; 10(1) : 52-60.
10. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma : effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992 ; 16(2) : 227-33.
11. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996 ; 224(6) : 756-64.
12. Stojadinovic A, Jaques DP, Leung DH, Healey JH, Brennan MF. Amputation for recurrent soft tissue sarcoma of the extremity : indications and outcome. Ann Surg Oncol 2001 ; 8(6) : 509-18.
13. Vrouenraets BC, Kroon BB, Ogilvie AC, van Geel AN, Nieweg OE, Swaak AJ, et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 1999 ; 6(4) : 405-12.
14. Broukaert P, Libert C, Everaerdt B, Fiers W. Selective species specificity of tumor necrosis factor for toxicity in the mouse. Lymphokine Cytokine Res 1992 ; 11 : 193-6.
15. Bonvalot S, Laplanche A, Lejeune F, Stoeckle E, Le Péchoux C, Vanel D, et al. Limb salvage with isolated perfusion for soft tissue sarcoma : could less TNF-alpha be better ? Ann Oncol 2005 ; 16(7) : 1061-8.
16. Bedard, A. Vataire, C. Desouche, C. Le Péchoux, J. Muret, D. Vanel, et al. A prospective database of 100 patients with locally soft tissue sarcoma treated by isolated limb perfusion with melphalan and TNFa 1mg. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007 : 10010.
17. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma : results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996 ; 14(2) : 479-89.
18. Aigner KR. Pelvic stop-flow infusion and hypoxic pelvic perfusion with mitomycin and melphalan for recurrent rectal cancer. Reg Cancer treatment 1994 ; 1 : 6-11.
19. Guadagni S, Aigner KR, Palumbo C, Cantore M, Fiorentini C, Pozone T, et al. Pharmacokinetics of mitomycin C in pelvic stop- flow infusion and hypoxic pelvic perfusion with and without hemofiltration : a pilot study of patients with recurrent unresectable rectal cancer. J Clin Pharmacol 1998 ; 38(10) : 936-44.
20. Wanebo HJ, Chung MA, Levy Al, Turk PS, Vezeridis MP, Belli-veau JF. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique. Ann Surg Oncol 1996 ; 3(3) : 295-303.
21. Begossi G, Belliveau JF, Wanebo HJ. Pelvic perfusion for advanced colorectal cancers. Surg Oncol Clin N Am 2008 ; 17(4) : 825-42.
22. Bonvalot S, Bonnay M, Drouard-Troalen L, Cavalcanti A, Le Pechoux C, Le Cesne A, et al. Pressure-suit combined with pelvic stop-flow : a feasibility study in a bovine model. Eur J Surg Oncol 2007 ; 33(1) : 114-8.
23. Wanebo HJ, DiSiena M, Begossi G, Belliveau J, Gustafson E. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. Ann Surg Oncol 2008 ; 15(4) : 1107-16.
24. Pohlen U, Rieger H, Kunick-Pohlen S, Berger G, Buhr HJ. Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome. Anticancer Res 2007 ; 27 (1B) : 667-74.
25. Strocchi E, laffaioli RV, Facchini G, Mantovani G, Ricci S, Cavallo G, et al. Stop-flow technique for loco-regional delivery of high dose chemotherapy in the treatment of advanced pelvic cancers. Eur J Surg Oncol 2004 ; 30(6) : 663-70.
26. Maruo T, Motoyama S, Hamana S, Yoshida S, Ohara N, Yamasaki M, et al. Percutaneous pelvic perfusion with extracorporeal chemofiltration for advanced uterine cervical carcinoma. Surg Oncol Clin N Am 2008 ; 1 7(4) : 843-56.
27. Bonvalot S, Muret J, Debaere T, Drouard-Troalen L, Bonniaud G, Morice P, et al. High response rates with isolated pelvic perfusion (IPP) with a pneumatic anti-shock garments (PASG) and low- dose TNF-α for locally advanced pelvic sarcomas and carcinomas : A phase II unicenter trial. J Clin Oncol 2008 ; 26 (May 20 suppl ; abstr 10586).
28. Muret J, Bonnet L, Bonvalot S, Israel P, Baguenard P, Chevalet M, et al. Tolérance anesthésique, respiratoire et hémodynamique d'une perfusion isolée de pelvis avec injection de TNF-a et de melphalan dans le traitement de sarcomes évolués du pelvis et de la racine des membres. Ann Fr Anesth Reanim 2006 ; 25 : R117.
29. Bonvalot S. Soft tissue sarcoma : improved quality of life with new surgical approaches. Bull Cancer 2002 ; 12 : 1045-52.
30. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. EORTC Soft Tissue and Bone Sarcoma Group.Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002 ; 38(4) : 543-9.